CCXI - ケモセントリックス (ChemoCentryx Inc.)

CCXIのニュース

   Amgen completes purchase of ChemoCentryx for $3.7 billion  2022/10/21 15:30:27 Business Journals
The deal includes FDA-approved Tavneos, a treatment for a group of autoimmune diseases that cause small vessel inflammation.
   ChemoCentryx shareholders approve $4.7B merger with Amgen (NASDAQ:CCXI)  2022/10/18 21:45:49 Seeking Alpha
ChemoCentryx shareholders have overwhelmingly approved Amgen''s (AMGN) $3.7B acquisition of the company.
   Amgen Stock Is Looking Interesting On The Dip (NASDAQ:AMGN)  2022/09/13 11:35:16 Seeking Alpha
Amgen continues to churn out respectable growth amidst a challenging economic backdrop. See why AMGN''s ChemoCentryx acquisition should bolster top-line growth.
   7 Dow Stocks With Superior Fundamentals  2022/09/06 18:55:35 InvestorPlace
Today I’m writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices. The index serves as a bellwether that tracks investors’ sentiment. These large-cap, well-known companies are widely regarded as safe havens from market volatility. With their remarkable longevity and solid fundamentals, these companies tend to be among the first businesses to recover from economic uncertainties. So far in 2022, the DJIA has lost about 13.5% of its value. By comparison, the Nasdaq 100 index and the S&P 500 index have fallen around 25% and 18%, respectively, so far this year. Today’s list of Dow stocks to buy includes prominent blue-chip names that have sold off significantly in 2022. As investors continue to flock to safe bets, these Dow-30 members could be primed for significant rebounds throughout the rest of the year. Here are the seven Dow stocks to buy that offer compelling buying opportunities for patient investors.
   ChemoCentryx''s Return On Capital Employed Insights  2022/09/01 14:20:27 Benzinga
According to data from Benzinga Pro, during Q2, ChemoCentryx ''s (NASDAQ: CCXI ) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. ChemoCentryx collected $5.46 million in revenue during Q1, but reported earnings showed a $38.61 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com
   Amgen completes purchase of ChemoCentryx for $3.7 billion  2022/10/21 15:30:27 Business Journals
The deal includes FDA-approved Tavneos, a treatment for a group of autoimmune diseases that cause small vessel inflammation.
   ChemoCentryx shareholders approve $4.7B merger with Amgen (NASDAQ:CCXI)  2022/10/18 21:45:49 Seeking Alpha
ChemoCentryx shareholders have overwhelmingly approved Amgen''s (AMGN) $3.7B acquisition of the company.
   Amgen Stock Is Looking Interesting On The Dip (NASDAQ:AMGN)  2022/09/13 11:35:16 Seeking Alpha
Amgen continues to churn out respectable growth amidst a challenging economic backdrop. See why AMGN''s ChemoCentryx acquisition should bolster top-line growth.
   7 Dow Stocks With Superior Fundamentals  2022/09/06 18:55:35 InvestorPlace
Today I’m writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices. The index serves as a bellwether that tracks investors’ sentiment. These large-cap, well-known companies are widely regarded as safe havens from market volatility. With their remarkable longevity and solid fundamentals, these companies tend to be among the first businesses to recover from economic uncertainties. So far in 2022, the DJIA has lost about 13.5% of its value. By comparison, the Nasdaq 100 index and the S&P 500 index have fallen around 25% and 18%, respectively, so far this year. Today’s list of Dow stocks to buy includes prominent blue-chip names that have sold off significantly in 2022. As investors continue to flock to safe bets, these Dow-30 members could be primed for significant rebounds throughout the rest of the year. Here are the seven Dow stocks to buy that offer compelling buying opportunities for patient investors.
   ChemoCentryx''s Return On Capital Employed Insights  2022/09/01 14:20:27 Benzinga
According to data from Benzinga Pro, during Q2, ChemoCentryx ''s (NASDAQ: CCXI ) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. ChemoCentryx collected $5.46 million in revenue during Q1, but reported earnings showed a $38.61 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com
   ChemoCentryx Q2 2022 Earnings Preview  2022/08/08 21:35:43 Seeking Alpha
ChemoCentryx (CCXI) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close
   Earnings Preview: ChemoCentryx  2022/08/08 14:13:58 Benzinga
ChemoCentryx (NASDAQ: CCXI ) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here''s what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.49. ChemoCentryx bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
   CHEMOCENTRYX, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CCXI and Encourages Investors to Contact the Firm  2022/08/08 00:05:00 GlobeNewswire
NEW YORK, Aug. 07, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of ChemoCentryx, Inc. (NASDAQ: CCXI) (“ChemoCentryx”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Amgen (NASDAQ: AMGN) (“Amgen”).
   Is Now A Good Time To Invest In ChemoCentryx Inc. (NASDAQ: CCXI)?  2022/08/05 17:00:00 Stocks Register
ChemoCentryx Inc. (NASDAQ:CCXI) shares, rose in value on Friday, August 05, with the stock price up by 0.18% to the previous day’s close as strong demand from buyers drove the stock to $50.52. Actively observing the price movement in the recent trading, the stock is buoying the session at $50.43, falling within a range of … Is Now A Good Time To Invest In ChemoCentryx Inc. (NASDAQ: CCXI)? Read More »
   Amgen bets on ChemoCentryx’s rare disease drug in $3.7 billion deal  2022/08/05 12:05:13 Express Pharma
Amgen has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for the therapy are expected to expire in 2029 The post Amgen bets on ChemoCentryx’s rare disease drug in $3.7 billion deal appeared first on Express Pharma .

calendar